CIPLA LIMITED
Clinical Trials
26
Trial Phases
2 Phases
Drug Approvals
21
Drug Approvals
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
News
Stempeutics Licenses Stem Cell Therapy Stempeucel to Japanese Partner for Critical Limb-Threatening Ischemia Treatment
Manipal Group-backed Stempeutics Research has signed a licensing agreement with Tokyo-listed Medinet to introduce Stempeucel, a stem cell therapy for Critical Limb-Threatening Ischemia (CLTI), into the Japanese market.
Eli Lilly Partners with Cipla to Expand Tirzepatide Access in India Through Dual-Brand Strategy
Eli Lilly has signed an agreement with Cipla to market its blockbuster weight-loss drug tirzepatide under the brand name Yurpeak in India, expanding access beyond Lilly's established presence.
Eupraxia Pharmaceuticals Announces Public Offering to Advance Extended-Release Drug Pipeline
Eupraxia Pharmaceuticals has filed for a public offering of common shares with underwriters having a 30-day option to purchase up to 15% additional shares to fund pipeline advancement.
Major Pharmaceutical Companies Face Surge in Generic Drug Patent Challenges in Early 2025
Major pharmaceutical companies including AstraZeneca, Novartis, and Astellas are defending patents for blockbuster drugs like Lynparza, Entresto, and Xtandi against generic manufacturers in early 2025.
ImmunoACT Achieves Profitability with India's First CAR-T Therapy, Treating Over 350 Cancer Patients
ImmunoACT reported ₹62 crore in revenue and ₹12 crore profit before tax in FY25, marking rare profitability for an Indian biotech startup in its first full year of operations.
ViiV Healthcare Expands Generic License for Long-Acting HIV Treatment to 133 Countries
ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool to allow generic production of cabotegravir for HIV treatment in 133 countries, including all low-income and Sub-Saharan African nations.
Cipla Plans Entry into India's Weight Management Market as Obesity Becomes Strategic Priority
Cipla is preparing to enter India's weight management segment to address rising demand for effective obesity solutions, as announced by CEO Umang Vohra in the company's 2024-25 annual report.
Biocon Races to Launch First Generic Semaglutide in Canada as Wegovy Patents Expire
Biocon Ltd. is seeking regulatory approval for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting Canada as its first major market entry by 2026.
Torrent Pharma Advances $2.4 Billion Acquisition of JB Chemicals in Major Industry Consolidation Move
Torrent Pharma is in advanced talks with KKR to acquire JB Chemicals and Pharmaceuticals for approximately Rs 20,734.61 crore ($2.4 billion), marking its largest acquisition to date.
Cipla Launches ZEMDRI (Plazomicin) in India to Combat Antimicrobial Resistance
• Cipla has introduced ZEMDRI (Plazomicin), a novel intravenous aminoglycoside treatment for complicated urinary tract infections (cUTI) including pyelonephritis in adult patients in India. • The drug demonstrates promising activity against multi-drug resistant bacteria, including Carbapenem-resistant Enterobacteriaceae (CRE), addressing a critical challenge in managing resistant infections in India. • ZEMDRI's approval was supported by the EPIC clinical trial, the first randomized controlled study of once-daily aminoglycoside therapy for cUTI treatment, with Cipla generating India-specific pathogen data to validate its effectiveness.